
Poseida Therapeutics PSTX
Quartalsbericht 2024-Q3
hinzugefügt 07.11.2024
Poseida Therapeutics Betriebsaufwand 2011-2026 | PSTX
Betriebsaufwand Jährlich Poseida Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 194 M | 190 M | 173 M | 127 M | 78.8 M | 40.6 M | 24.6 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 194 M | 24.6 M | 118 M |
Betriebsaufwand Vierteljährlich Poseida Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52 M | 57.7 M | 52.7 M | - | 45.6 M | 47.9 M | 49.9 M | - | 44.5 M | 44.2 M | 58.4 M | - | 41.6 M | 44.9 M | 37.5 M | - | 33.5 M | 29.4 M | 28.3 M | - | 20.8 M | 28.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 58.4 M | 20.8 M | 42.2 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
BioLineRx Ltd.
BLRX
|
28.1 M | $ 2.25 | 1.81 % | $ 908 M | ||
|
BioNTech SE
BNTX
|
512 M | $ 91.28 | 0.11 % | $ 27.2 B | ||
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 330.34 | 3.6 % | $ 43.3 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
8.73 M | $ 0.44 | -16.64 % | $ 5.04 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 24.98 | 1.17 % | $ 3.05 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
85.3 M | $ 10.14 | -0.29 % | $ 135 M | ||
|
Cardiff Oncology
CRDF
|
49.6 M | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
33.9 M | $ 0.53 | -3.07 % | $ 6.98 M | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Crinetics Pharmaceuticals
CRNX
|
173 M | $ 37.7 | 1.26 % | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
668 M | $ 49.15 | -0.73 % | $ 4.42 B | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
51.4 M | $ 2.96 | -1.0 % | $ 252 M | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CytomX Therapeutics
CTMX
|
98.6 M | $ 4.4 | -3.51 % | $ 607 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Citius Pharmaceuticals
CTXR
|
42 M | $ 0.86 | 0.67 % | $ 5.79 M | ||
|
Cue Biopharma
CUE
|
54 M | $ 0.18 | -1.61 % | $ 17.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
47.6 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | ||
|
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.09 | -0.97 % | $ 437 M | ||
|
Cyclerion Therapeutics
CYCN
|
5.63 M | $ 4.15 | -32.52 % | $ 10.4 M | ||
|
Daré Bioscience
DARE
|
14.3 M | $ 1.81 | 4.02 % | $ 20.2 M | ||
|
DBV Technologies S.A.
DBVT
|
153 M | $ 20.36 | -3.32 % | $ 2.84 B | ||
|
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
158 M | $ 8.22 | 2.37 % | $ 225 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Denali Therapeutics
DNLI
|
502 M | $ 19.38 | -6.15 % | $ 3.19 B | ||
|
Dyadic International
DYAI
|
10.1 M | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
Celldex Therapeutics
CLDX
|
58.1 M | $ 31.37 | 1.0 % | $ 2.08 B | ||
|
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M |